# The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction

> **NCT06732648** · PHASE2,PHASE3 · RECRUITING · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 725 (estimated)

## Conditions studied

- Severe Cerebral Edema Following Large Hemispheric Infarction

## Interventions

- **DRUG:** HRS8179 injection
- **DRUG:** HRS8179 blank preparation.

## Key facts

- **NCT ID:** NCT06732648
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 725 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732648, "The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06732648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*